Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether summary of findings: pioglitazone monotherapy changes all‐cause mortality (N) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thiazolidinediones Diagnostic criteria: 2 trials applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT) (Jin 2009; Zeng 2013). No medical association recommended the cut‐off points applied in Maji ... · people at increased risk for developing type 2 diabetes
Summary of findings table for metformin showed no clear difference in thiazolidinediones Diagnostic criteria: 2 trials applied the WHO… compared with diet and exercise or another antidiabetic drug (low certainty).
1 finding from 1 review
Intensive diet plus exercise · people at increased risk for developing type 2 diabetes
4 findings from 1 review
Show 1 more finding
Acarbose · people at increased risk for developing type 2 diabetes
3 findings from 1 review
Thiazolidinediones · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Placebo or diet and exercise · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Placebo or diet and exercise Description: SF‐36 to evaluate the health utility index SF‐6D (physical component summaries and mental component summaries) Minimal important difference: difference in scores between groups of at least 3% · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Placebo or diet and exercise Description: direct medical costs · people at increased risk for developing type 2 diabetes
1 finding from 1 review